INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA

Their core work

ITTM is a Luxembourg-based SME specializing in health data management and informatics for translational medicine — the bridge between laboratory research and clinical application. They build and operate IT infrastructure for large-scale clinical and biomarker studies, handling tasks like data governance, multi-omics integration, patient data harmonization, and computational immunology. Their work spans drug safety assessment, immune profiling, and AI-driven clinical decision support, making them a technical backbone for pharmaceutical and biomedical research consortia across Europe.

What they specialise in

How they've shifted over time

ITTM's early work (2017–2019) centred on health data infrastructure — building EHR exchange systems, digital health platforms, and occupational health tools (Smart4Health, GLIOTRAIN). From 2019 onward, they shifted decisively toward immune-mediated disease research and precision medicine, with deep involvement in biomarker discovery, multi-omics data integration, and computational immunology (BIOMAP, ImmUniverse, imSAVAR, T2EVOLVE). Their most recent projects (2021+) add AI-driven clinical decision support and advanced cell therapy informatics, signalling a move toward more specialized, high-value analytical roles in precision oncology and immunotherapy.

ITTM is moving from general health IT infrastructure toward specialized data analytics for immunotherapy and precision oncology — expect them to seek roles managing complex multi-omics and real-world evidence pipelines.

How they like to work

ITTM operates exclusively as a consortium participant, never as coordinator, which positions them as a reliable specialist contributor rather than a project driver. With 220 unique partners across 23 countries in just 10 projects, they work in very large consortia (typically 20+ members) — characteristic of IMI and large RIA health projects. This broad network suggests they are easy to integrate into new partnerships and comfortable operating within complex multi-site governance structures.

ITTM has collaborated with 220 unique partners across 23 countries, an exceptionally wide network for a 10-project SME. Their partnerships span all major EU research nations, with strong ties to pharmaceutical-academic consortia typical of IMI-style health projects.

What sets them apart

ITTM fills a specific niche that few SMEs occupy: they are the IT and data management layer for large translational medicine consortia. While pharma companies bring compounds and universities bring biology, ITTM brings the informatics infrastructure that ties multi-site, multi-omics clinical studies together. Their Luxembourg base also offers advantages for health data governance given the country's strong data protection framework and central European location.

Highlights from their portfolio

• Smart4Health
  Their largest project (EUR 2.25M) — building a citizen-centred cross-border electronic health record exchange platform, demonstrating capacity to handle major health data infrastructure.
• BIOMAP
  A flagship biomarker discovery project in atopic dermatitis and psoriasis combining deep phenotyping, molecular profiling, and single-cell analysis across a large European consortium.
• OPTIMA
  Their most recent major project (EUR 787K) applying AI and real-world evidence to optimize solid tumour treatment across Europe — signals their future direction.